European Archives - Page 160 of 1146 - European Medical Journal

Does IV Lidocaine Boost Postoperative Gut Function Recovery?

The ALLEGRO trial aimed to determine whether 2% IV lidocaine could speed up the return of gut function following colon resection surgery.

Enhancing Prostate Cancer Detection in Diverse Populations

Stockholm3 demonstrates significant potential to enhance prostate cancer detection in diverse populations while maintaining similar sensitivity to PSA.

Light Waves Could Transform Blood Pressure Monitoring and Cancer Care

Optical devices using light waves improve blood pressure monitoring and track cancer treatment response in real-time.

COVID-19 Vaccination During Pregnancy Found Safe for Neonatal Health

A new study from the Netherlands has provided reassuring evidence on the safety of COVID-19 vaccination during pregnancy.

Synergistic Effects of Obesity and Diabetes on HCC Recurrence

Obesity and diabetes mellitus are widely acknowledged risk factors for the development of steatotic liver diseases, contributing to liver cirrhosis and HCC.

Late-Onset Rheumatoid Arthritis Linked to Worse Outcomes

Late-onset rheumatoid arthritis worsens physical function and raises risks of adverse events, including death and malignancy, compared to younger-onset cases.

Blood Pressure Fluctuations Linked to Cognitive Decline in Older Adults

A new study highlights the link between visit-to-visit blood pressure variability (BPV) and cognitive decline in older adults….

Blood Eosinophils and IL-8 Linked to Lung Decline in Asthma

Rising blood eosinophil counts and high sputum IL-8 levels predict accelerated lung function decline in asthma, highlighting key biomarkers for monitoring.

Revised Masking and Testing Strategies Reduce COVID-19 Spread

Results showed that ending universal testing and masking correlated with a notable increase in hospital-onset respiratory viral infections compared to community-onset cases.

Lung Clearance Index Shows ETI Benefits in Cystic Fibrosis

LCI detects lung function improvements in cystic fibrosis patients on ETI therapy, even when FEV1 changes are minimal, highlighting its clinical value.